BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Bioequivalence Study of BAY77-1931 Granule
Phase 1
Completed
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tabletDrug: Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 59
- Registration Number
- NCT01053676
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Completed
- Conditions
- Disease, Pulmonary
- Interventions
- Drug: Ciprofloxacin (Cipro inhale, BAYQ3939)Drug: Placebo
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT01052298
Gadobutrol Magnevist-controlled Body Study
Phase 3
Completed
- Conditions
- Magnetic Resonance Imaging
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 370
- Registration Number
- NCT01050829
Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 31
- Registration Number
- NCT01049022
BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia
Phase 3
Completed
- Conditions
- Pneumonia, AspirationLung Abscess
- Interventions
- Drug: Avelox (Moxifloxacin, BAY12-8039)Drug: Sulbactam/Ampicillin
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2010-01-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 139
- Registration Number
- NCT01045902
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
Completed
- Conditions
- Liver NeoplasmsAdenomaCarcinomaLiver Abscess
- Interventions
- Drug: Gadoxetic Acid Disodium (Eovist, BAY86-4873)
- First Posted Date
- 2010-01-06
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 52
- Registration Number
- NCT01043523
Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Positron-Emission TomographyAlzheimer's Disease
- Interventions
- Drug: F-18 FEDAA1106 (BAY85-8101)
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT01035164
Symptomatic Treatment of Common Cold Symptoms
Phase 4
Completed
- Conditions
- Common Cold
- Interventions
- Drug: PlaceboDrug: Aspirin (Acetylsalicylic acid, BAYE4465)
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2009-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 388
- Registration Number
- NCT01033526
Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium
Phase 1
Completed
- Conditions
- Ovulation InhibitionContraception
- Interventions
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 42
- Registration Number
- NCT01031355
Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers
Phase 1
Completed
- Conditions
- Positron-Emission TomographyMultiple Sclerosis
- Interventions
- Drug: F-18 FEDAA1106 (BAY85-8101)
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT01031199
© Copyright 2025. All Rights Reserved by MedPath